Profound Medical Analyst Ratings
Profound Medical Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/28/2023 | 32.53% | Stifel | → $11 | Initiates Coverage On | → Hold |
08/04/2023 | — | Raymond James | Downgrades | Strong Buy → Outperform | |
05/11/2023 | 116.87% | TD Cowen | $14 → $18 | Maintains | Outperform |
05/11/2023 | 89.76% | Alliance Global Partners | $13.15 → $15.75 | Maintains | Buy |
03/21/2023 | 20.48% | Jefferies | $5.5 → $10 | Downgrades | Buy → Equal-Weight |
11/04/2022 | — | Raymond James | Upgrades | Outperform → Strong Buy | |
03/07/2022 | 68.67% | Cowen & Co. | $28 → $14 | Maintains | Outperform |
02/22/2022 | 177.11% | Raymond James | $28 → $23 | Downgrades | Strong Buy → Outperform |
09/15/2020 | — | Jefferies | Initiates Coverage On | → Buy | |
09/10/2020 | 165.06% | Lake Street | → $22 | Initiates Coverage On | → Buy |
04/01/2020 | 80.72% | Cowen & Co. | → $15 | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/28/2023 | 32.53% | Stifel | → 11 美元 | 啓動覆蓋範圍開啓 | → 按住 |
08/04/2023 | — | 雷蒙德·詹姆 | 降級 | 強勢買入 → 跑贏大盤 | |
05/11/2023 | 116.87% | TD Cowen | 14 美元 → 18 美元 | 維護 | 跑贏大盤 |
05/11/2023 | 89.76% | 聯盟全球合作伙伴 | 13.15 美元 → 15.75 美元 | 維護 | 買 |
03/21/2023 | 20.48% | 傑富瑞集團 | 5.5 美元 → 10 美元 | 降級 | 購買 → 等量權重 |
2022 年 4 月 11 日 | — | 雷蒙德·詹姆 | 升級 | 跑贏大盤 → 強勢買入 | |
03/07/2022 | 68.67% | Cowen & Co. | 28 美元 → 14 美元 | 維護 | 跑贏大盤 |
02/22/2022 | 177.11% | 雷蒙德·詹姆 | 28 美元 → 23 美元 | 降級 | 強勢買入 → 跑贏大盤 |
2020 年 9 月 15 日 | — | 傑富瑞集團 | 啓動覆蓋範圍開啓 | → 購買 | |
2020 年 10 月 9 日 | 165.06% | 湖街 | → 22 美元 | 啓動覆蓋範圍開啓 | → 購買 |
2020 年 1 月 4 日 | 80.72% | Cowen & Co. | → 15 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Profound Medical (PROF)?
Profound Medical(PROF)的目標價格是多少?
The latest price target for Profound Medical (NASDAQ: PROF) was reported by Stifel on November 28, 2023. The analyst firm set a price target for $11.00 expecting PROF to rise to within 12 months (a possible 32.53% upside). 5 analyst firms have reported ratings in the last year.
Stifel於2023年11月28日公佈了Profound Medical(納斯達克股票代碼:PROF)的最新目標股價。該分析公司將目標股價定爲11.00美元,預計PROF將在12個月內升至12個月內(可能上漲32.53%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Profound Medical (PROF)?
Profound Medical(PROF)的最新分析師評級是多少?
The latest analyst rating for Profound Medical (NASDAQ: PROF) was provided by Stifel, and Profound Medical initiated their hold rating.
Stifel提供了Profuct Medical(納斯達克股票代碼:PROF)的最新分析師評級,而Profound Medical則啓動了持有評級。
When is the next analyst rating going to be posted or updated for Profound Medical (PROF)?
Profound Medical(PROF)的下一次分析師評級將在何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Profound Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Profound Medical was filed on November 28, 2023 so you should expect the next rating to be made available sometime around November 28, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Profound Medical的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。Profound Medical的最新評級是在2023年11月28日公佈的,因此您應該預計下一個評級將在2024年11月28日左右公佈。
Is the Analyst Rating Profound Medical (PROF) correct?
分析師對深遠醫療(PROF)的評級是否正確?
While ratings are subjective and will change, the latest Profound Medical (PROF) rating was a initiated with a price target of $0.00 to $11.00. The current price Profound Medical (PROF) is trading at is $8.30, which is within the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但最新的Profound Medical(PROF)評級已啓動,目標股價爲0.00美元至11.00美元。Profound Medical(PROF)目前的交易價格爲8.30美元,在分析師的預測區間內。
譯文內容由第三人軟體翻譯。